Can I Take Retatrutide During Pregnancy?

The short answer is no. Retatrutide should not be used during pregnancy, and women should stop the medication well before attempting to conceive. While limited human data exists specifically for retatrutide, the entire GLP-1 medication class is contraindicated in pregnancy based on animal reproductive studies and the fundamental incompatibility of intentional weight loss with healthy fetal development (Jastreboff et al., NEJM 2023).

Why Retatrutide Is Contraindicated in Pregnancy

Animal Study Concerns

GLP-1 receptor agonists have shown adverse effects in animal reproduction studies including reduced fetal growth, skeletal abnormalities, and increased pregnancy loss at clinically relevant doses. While animal studies do not always predict human outcomes, the consistency of these findings across multiple GLP-1 medications creates a significant safety concern that precludes use during pregnancy.

Caloric Restriction and Fetal Development

Even if retatrutide itself had no direct effects on the fetus, the profound appetite suppression and caloric restriction it causes are fundamentally incompatible with healthy pregnancy. Fetal development requires adequate caloric and nutritional intake. Significant caloric deficit during pregnancy increases risks of low birth weight, preterm delivery, neural tube defects, and developmental delays.

GI Effects and Nutrient Absorption

Retatrutide's delayed gastric emptying and GI side effects (nausea, vomiting) compound the nutritional risks. Morning sickness is already common in pregnancy; adding GLP-1-mediated nausea on top could lead to severe nutritional deficiency during critical developmental windows.

When to Stop Before Conceiving

Based on guidance for the GLP-1 class:

• Planned pregnancy: Stop retatrutide at least 2 months before attempting to conceive. This allows the medication to fully clear and gastric function to normalize.
• Use effective contraception throughout retatrutide treatment (see our article on retatrutide and birth control)
• Begin prenatal vitamins at least 1 month before discontinuing retatrutide, as folate needs are critical in early pregnancy

What If You Discover You Are Pregnant While on Retatrutide

If you discover you are pregnant while taking retatrutide:

• Stop retatrutide immediately. Do not take your next scheduled dose.
• Contact your OB/GYN and prescribing provider as soon as possible.
• Do not panic. Many women have been exposed to GLP-1 medications in early pregnancy (before knowing they were pregnant) and have had healthy outcomes. The risk is not zero, but it is not a guarantee of harm.
• Begin prenatal care immediately with appropriate screening.
• Document your medication history including the last injection date and dose for your obstetric team.

The "Ozempic Baby" Phenomenon

GLP-1 medications have been widely reported to restore fertility in women with obesity-related infertility. Weight loss of 10-15% can restart ovulation in women with PCOS or obesity-related anovulation. This fertility boost has led to numerous unplanned pregnancies (dubbed "Ozempic babies" in media coverage). With retatrutide's even more dramatic weight loss, this effect may be more pronounced, making reliable contraception essential.

Breastfeeding

It is not known whether retatrutide is excreted in human breast milk. Given the lack of data and the potential for serious adverse effects in nursing infants, retatrutide should not be used while breastfeeding. Additionally, intentional weight loss during breastfeeding can reduce milk supply and compromise the nutritional quality of breast milk.

After Pregnancy: Resuming Treatment

After pregnancy and breastfeeding (if applicable), retatrutide can be resumed. Many women gain weight during and after pregnancy and benefit from resuming GLP-1 therapy to address postpartum weight retention. Your provider will likely restart at the initial dose and re-titrate, as your tolerance may have changed during the medication-free period.

Weight Management During Pregnancy

For women who were on retatrutide and stop for pregnancy, managing weight gain during pregnancy is a concern. Current ACOG guidelines recommend 11-20 pounds of weight gain for women with obesity (BMI 30+). Working with your OB/GYN on appropriate nutrition, physical activity, and weight gain targets during pregnancy is the safe approach, not medication.

GLP-1 Treatment With Family Planning Support

Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who discuss family planning and contraception as part of comprehensive GLP-1 treatment. Learn how Trimi works.

Frequently Asked Questions

Is retatrutide safe during any trimester?

No. Retatrutide is contraindicated during all trimesters of pregnancy. There is no safe period for GLP-1 medication use during pregnancy.

I took retatrutide before I knew I was pregnant. Is my baby okay?

Early inadvertent exposure does not guarantee harm, and many healthy pregnancies have occurred after early GLP-1 exposure. However, stop the medication immediately and inform your OB/GYN so appropriate monitoring can be arranged.

How long does retatrutide stay in the body after stopping?

Based on its pharmacokinetic profile, retatrutide is expected to be substantially cleared within 4-6 weeks after the last injection. The recommended 2-month washout before conception provides an additional safety margin.

Can retatrutide cause birth defects?

Animal studies have shown reproductive toxicity including skeletal abnormalities. Human data is insufficient to confirm or rule out birth defect risk. The precautionary approach is to avoid exposure entirely during pregnancy.